Windows 11 remains the driver of growth in PCs, not AIstake com casino games plinko 。

SLNG Stock Soars to 52-Week High, Reaching $5.37Washington, Dec 3 (AP) President-elect Donald Trump has named billionaire investment banker Warren Stephens as his envoy to Britain, a prestigious posting for the Republican donor whose contributions this year included $2 million to a Trump-backing super PAC. Trump, in a post on his Truth Social site Monday evening, announced he was selecting Stephens to be the U.S. ambassador to the Court of Saint James. The Senate is required to confirm the choice. “Warren has always dreamed of serving the United States full time. I am thrilled that he will now have that opportunity as the top Diplomat, representing the U.S.A. to one of America's most cherished and beloved Allies,” Trump said in in his post. Stephens is the chairman, president and CEO of Little Rock, Arkansas-based financial services firm Stephens Inc., having taken over the firm from his father. Trump has already named many of his nominees for his Cabinet and high-profile diplomatic posts, assembling a roster of staunch loyalists. Over the weekend, Trump announced he intends to nominate real estate developer Charles Kushner, father of Trump's son-in-law Jared Kushner, to serve as ambassador to France. During his first term, Trump selected Robert “Woody” Johnson, a contributor to his campaign and the owner of the New York Jets football team, as his representative to the United Kingdom. (AP) NB NB (This story has not been edited by THE WEEK and is auto-generated from PTI)

Pet passports for dogs, cats and ferrets to travel within UK ‘an outrage’

Video game ends ‘collaboration’ with Conor McGregor

Pet passports for dogs, cats and ferrets to travel within UK ‘an outrage’

US sanctions founder of Georgia’s ruling political partyPrime Minister meets Egyptian counterpartJason Kidd Expects 2 Dallas Mavericks to 'Pick up the Slack'

BEIRUT (AP) — Israel's military launched airstrikes across Lebanon on Monday, unleashing explosions throughout the country and killing at least 31 while Israeli leaders appeared to be closing in on a negotiated ceasefire with the Hezbollah militant group. Israeli strikes hit commercial and residential buildings in Beirut as well as in the port city of Tyre. Military officials said they targeted areas known as Hezbollah strongholds. They issued evacuation orders for Beirut's southern suburbs, and strikes landed across the city, including meters from a Lebanese police base and the city's largest public park. The barrage came as officials indicated they were nearing agreement on a ceasefire, while Israeli Prime Minister Benjamin Netanyahu 's Security Cabinet prepared to discuss an offer on the table. Massive explosions lit up Lebanon's skies with flashes of orange, sending towering plumes of smoke into the air as Israeli airstrikes pounded Beirut’s southern suburbs Monday. The blasts damaged buildings and left shattered glass and debris scattered across nearby streets. No casualties were reported after many residents fled the targeted sites. Some of the strikes landed close to central Beirut and near Christian neighborhoods and other targets where Israel had issued evacuation warnings, including in Tyre and Nabatiyeh province. Israeli airstrikes also hit the northeast Baalbek-Hermel region without warning. Lebanon’s Health Ministry said Monday that 26 people were killed in southern Lebanon, four in the eastern Baalbek-Hermel province and one in Choueifat, a neighborhood in Beirut's southern suburbs that was not subjected to evacuation warnings on Monday. The deaths brought the total toll to 3,768 killed in Lebanon throughout 13 months of war between Israel and Hezbollah and nearly two months since Israel launched its ground invasion. Many of those killed since the start of the war between Israel and Hezbollah have been civilians , and health officials said some of the recovered bodies were so severely damaged that DNA testing would be required to confirm their identities. Israel says it has killed more than 2,000 Hezbollah members. Lebanon's Health Ministry says the war has displaced 1.2 million people. Israeli ground forces invaded southern Lebanon in early October, meeting heavy resistance in a narrow strip of land along the border. The military had previously exchanged attacks across the border with Hezbollah, an Iran-backed militant group that began firing rockets into Israel the day after the war in Gaza began last year. Lebanese politicians have decried the ongoing airstrikes and said they are impeding U.S.-led ceasefire negotiations. The country's deputy parliament speaker accused Israel of ramping up its bombardment in order to pressure Lebanon to make concessions in indirect ceasefire negotiations with Hezbollah. Elias Bousaab, an ally of the militant group, said Monday that the pressure has increased because “we are close to the hour that is decisive regarding reaching a ceasefire.” Israeli officials voiced similar optimism Monday about prospects for a ceasefire. Mike Herzog, the country's ambassador to Washington, earlier in the day told Israeli Army Radio that several points had yet to be finalized. Though any deal would require agreement from the government, Herzog said Israel and Hezbollah were “close to a deal." “It can happen within days,” he said. Israeli officials have said the sides are close to an agreement that would include withdrawal of Israeli forces from southern Lebanon and a pullback of Hezbollah fighters from the Israeli border. But several sticking points remain. Two Israeli officials told The Associated Press that Netanyahu’s security Cabinet had scheduled a meeting for Tuesday, but they said it remained unclear whether the Cabinet would vote to approve the deal. The officials spoke on condition of anonymity because they were discussing internal deliberations. Danny Danon, Israel’s U.N. ambassador, told reporters Monday that he expected a ceasefire agreement with Hezbollah to have stages and to be discussed by leaders Monday or Tuesday. Still, he warned, “it’s not going to happen overnight.” After previous hopes for a ceasefire were dashed, U.S. officials cautioned that negotiations were not yet complete and noted that there could be last-minute hitches that either delay or destroy an agreement. "Nothing is done until everything is done," White House national security spokesman John Kirby said Monday. The proposal under discussion to end the fighting calls for an initial two-month ceasefire during which Israeli forces would withdraw from Lebanon and Hezbollah would end its armed presence along the southern border south of the Litani River. The withdrawals would be accompanied by an influx of thousands more Lebanese army troops, who have been largely sidelined in the war, to patrol the border area along with an existing U.N. peacekeeping force . Western diplomats and Israeli officials said Israel is demanding the right to strike in Lebanon if it believes Hezbollah is violating the terms. The Lebanese government has said that such an arrangement would authorize violations of the country's sovereignty. A ceasefire could mark a step toward ending the regionwide war that ballooned after Hamas-led militants stormed into southern Israel on Oct. 7, 2023, killing some 1,200 people, mostly civilians, and abducting another 250 . The lack of a ceasefire has emerged as a political liability for Israeli leaders including Netanyahu, particularly while 60,000 Israelis remain away from their homes in the country's north after more than a year of cross-border violence. Hezbollah rockets have reached as far south into Israel as Tel Aviv. At least 75 people have been killed, more than half of them civilians. More than 50 Israeli soldiers died fighting in the ground offensive in Lebanon. The Israeli military said about 250 projectiles were fired Sunday, with some intercepted. A ceasefire between Israel and Hezbollah, the strongest of Iran’s armed proxies , is expected to significantly calm regional tensions that have led to fears of a direct, all-out war between Israel and Iran. It’s not clear how the ceasefire will affect the Israel-Hamas war in Gaza. Hezbollah had long insisted that it would not agree to a ceasefire until the war in Gaza ends, but it dropped that condition. A top Hamas official in Lebanon said the Palestinian militant group would support a ceasefire between its Lebanese ally Hezbollah and Israel, despite Hezbollah’s previous promises to stop the fighting in Lebanon only if the war in Gaza ends. “Any announcement of a ceasefire is welcome. Hezbollah has stood by our people and made significant sacrifices,” Osama Hamdan of Hamas' political wing told the Lebanese broadcaster Al-Mayadeen, which is seen as politically allied with Hezbollah. While the ceasefire proposal is expected to be approved if Netanyahu brings it to a vote in his security Cabinet, one hard-line member, National Security Minister Itamar Ben-Gvir, said he would oppose it. He said on X that a deal with Lebanon would be a “big mistake” and a “missed historic opportunity to eradicate Hezbollah.” If the ceasefire talks fail, Jordanian Foreign Minister Ayman Safadi said, “it will mean more destruction and more and more animosity and more dehumanization and more hatred and more bitterness.” Speaking at a G7 meeting in Fiuggi, Italy, the last summit of its kind before U.S. President Joe Biden leaves office, Safadi said such a failure "will doom the future of the region to more conflict and more killing and more destruction.” Federman reported from Jerusalem and Metz from Rabat, Morocco. Associated Press writers Edith M. Lederer at the United Nations, Nicole Winfield in Fiuggi, Italy, and Aamer Madhani in Washington contributed to this report. Find more of AP’s war coverage at https://apnews.com/hub/israel-hamas-warA popular video game developer has decided to pull content featuring Irish MMA fighter Conor McGregor from sale, after a woman who said he raped her won a civil claim for damages against him. Nikita Hand, who accused the sportsman of raping her in a Dublin hotel in December 2018, won her claim against him for damages in a civil case at the High Court in the Irish capital. The jury delivered its verdict on Friday. The total amount of damages awarded to Hand by the jury was 248,603.60 euros (£206,714.31). Mr McGregor made no comment as he left court but later posted on social media that he intends to appeal. The Irish athlete has featured in multiple video games, including voice-acting a character bearing his likeness in additional downloadable content in the Hitman series. Mr McGregor’s character featured as a target for the player-controlled assassin in the game. In light of the recent court ruling regarding Conor McGregor, IO Interactive has made the decision to cease its collaboration with the athlete, effective immediately. We take this matter very seriously and cannot ignore its implications. Consequently, we will begin removing all... — HITMAN (@Hitman) November 25, 2024 IO Interactive, the Danish developer and publisher of Hitman, said in a statement: “In light of the recent court ruling regarding Conor McGregor, IO Interactive has made the decision to cease its collaboration with the athlete, effective immediately. “We take this matter very seriously and cannot ignore its implications. “Consequently, we will begin removing all content featuring Mr McGregor from our storefronts starting today.” Mr McGregor had faced an accusation that he “brutally raped and battered” Ms Hand at a hotel in south Dublin in December 2018. The Irish sports star previously told the court he had consensual sex with Ms Hand in a penthouse at the Beacon Hotel. Ms Hand was taken in an ambulance to the Rotunda Hospital the following day where she was assessed in the sexual assault treatment unit. A paramedic who examined Ms Hand the day after the assault had told the court she had not seen “someone so bruised” in a long time.

Canada is launching a new online ad campaign cautioning asylum-seekers that making an immigration claim is “not easy.” In a statement provided to the Star on Monday, spokesperson for the Ministry of Immigration, Refugees and Citizenship Michelle Carbert confirmed the campaign, meant to equip people early in their asylum journey with “real facts,” will launch early next year and run through March. By mid-January, those searching the web with certain immigration inquiries will be met with sponsored content titled, “Canada’s asylum system - Asylum Facts.” Carbert said the campaign will target “all searches” relating to claiming asylum in Canada, which the ministry identified using Google’s Keyword Planner. The ads, expected to reach global audiences, will be translated into 11 different languages, including Spanish, Urdu, Ukrainian, Hindi and Tamil, Carbert said. The initiative comes about a week after Immigration Minister Marc Miller announced , set to be proposed in the coming weeks. In recent weeks, the governing Liberals, who have long championed Canada as one of the most welcoming countries in the world, have displayed a marked shift in tone on the immigration file. Those searching the web with certain immigration inquiries will be met with sponsored content titled, “Canada’s asylum system - Asylum Facts,” the ministry said. Canada has seen a spike in asylum claims in recent years, according to federal data — from 2019 to 2023, the number of claims filed rose by 125 per cent. As of October, over 260,000 claims are awaiting resolution. The average wait time to process each is currently around 44 months. in November, Immigration Minister Marc Miller said Canada’s asylum and refugee system is not working the way it should due to volume and inefficiency, and that he planned to propose further reforms in an effort to improve efficiency. According to Miller, a “growing” number of claims are not being made at regular ports of entry, but by those already inland. An increasing number of these claims, Miller said, are being filed by people on student visas, hoping to extend their stays. “The growing claims that we see now, inland, are not unexpected,” the minister said. “They’re ones that we saw with people having increasingly fewer hopes to stay in Canada, and being counselled to file, I think unjustly, asylum claims where they shouldn’t have the ability to do so.” In recent weeks, Prime Minister Justin Trudeau and Ontario Premier Doug Ford have joined Miller in who are exacerbating the challenges faced by Canada’s immigration system by coaching applicants through erroneous or even fraudulent processes. When reached for comment, NDP immigration critic Jenny Kwan said the new measures are an abrupt shift from past policy. “This about face from Prime Minister Trudeau is a shameless and insidious attempt to use newcomers such as migrants, international students, and asylum seekers as political cover,” Kwan said in a statement emailed to the Star. It’s a dangerous game on Trudeau’s part, said Kwan, in trying to “shift the blame for his failures” to asylum seekers — one she called “a recipe to further hype-up hate, resentment and discrimination toward racialized people. “Instead of wasting $250,000 on advertising, they should be investing those resources in processing applications,” said Kwan. Immigration, Refugees, and Citizenship Canada has run each year since 2018. In total, the Liberals spent an estimated $250,000 on this year’s project — about a third of the total amount spent ($768,000) on all annual advertising geared toward immigration in the last six years.Trésorerie et équivalents de trésorerie à 13,9 millions d’euros au 30 septembre 2023. Chiffre d’affaires de 1,3 millions d’euros sur les neuf premiers mois de 2024. Emission de certificats de redevance le 18 juillet 2024, pour un montant de 20,1 millions d'euros. En tenant compte de la réception de €94.1 million brut à la suite de la réalisation de la première partie de la première tranche de la levée de fonds annoncée le 14 octobre 2024 2 , et le versement du paiement d’étape par CTTQ reçu le 18 novembre 2024, la Société estime que ses liquidités, équivalents de liquidités et dépôts lui permettraient de financer ses opérations jusqu'à la fin du deuxième trimestre 2025 3 . Daix (France), New York City (New York, Etats-Unis) , le 21 novembre 2024 – Inventiva (Euronext Paris and Nasdaq :IVA) (la « Société »), société biopharmaceutique spécialisée dans le développement clinique de petites molécules administrées par voie orale pour le traitement des patients atteints de stéatohépatite associée à un dysfonctionnement métabolique (« MASH »), également connue sous le nom de stéatohépatite non alcoolique (« NASH »), et d’autres maladies avec un besoin médical non satisfait, publie aujourd’hui ses informations financières des neufs premiers mois clos au 30 septembre 2024. Trésorerie et équivalents de trésorerie Au 30 septembre 2024, la Société a enregistré 13,9 millions d’euros de trésorerie et équivalents de trésorerie, contre 26,9 millions d’euros, 0,01 million d’euros de dépôts à court terme 4 et 9,0 millions d’euros de dépôts long terme 5 au 31 décembre 2023. Les flux nets de trésorerie consommés par les activités opérationnelles se sont élevés à - 64,2 millions d’euros pour les neufs premiers mois de 2024, contre – 69,0 millions d’euros sur la même période en 2023, soit une baisse de 7,0%. Les dépenses en R&D, principalement en raison du développement de l’essai clinique avec lanifibranor dans la MASH/NASH, pour les neuf premiers mois de 2024 se sont élevées à 71,7 millions d'euros, soit une baisse de 10,0 % par rapport aux 79,6 millions d'euros pour les neuf premiers mois de 2023. La baisse des dépenses en R&D pendant la période est principalement due à la pause temporaire et volontaire dans le recrutement de patients dans l'essai clinique de Phase 3 NATiV3 avec lanifibranor dans la MASH/NASH (« NATiV3 »), à la suite d’effets indésirables graves et inattendus (« EIGI ») ou Suspected Unexpected Serious Adverse Reaction (« SUSAR ») précédemment rapportée au premier trimestre de 2024 et, dans une moindre mesure, à la fin de l'essai de Phase 2a LEGEND avec lanifibranor en combinaison avec empagliflozine chez des patients atteints de MASH/NASH et de diabète de type 2 (« T2D »). Les dépenses en R&D ont commencé à augmenter comme prévu au second semestre 2024 suite au redémarrage du screening des patients pour NATiV3, et conformément aux activités prévues dans le développement clinique et aux coûts associés de NATiV3 pour le second semestre 2024. Les flux nets de trésorerie générés par les opérations d’investissement se sont élevés à 8,7 millions d’euros pour les neuf premiers mois de 2024, contre – 3,5 millions d’euros consommés sur la même période en 2023. Cet écart est principalement dû à la variation des dépôts à terme entre les deux périodes. Les flux nets de trésorerie générés par les activités de financement pour les neuf premiers mois de 2024 se sont élevés à 42,3 millions d’euros , contre 30,2 millions d’euros sur la même période en 2023. Ce changement est dû (i) au tirage en janvier 2024, de la deuxième tranche de 25 millions d'euros dans le cadre de l’accord de prêt non assorti de sûretés accordé par la Banque Européenne d’Investissement (« BEI ») et accompagné de l’émission de 3.144.654 bons de souscription d'actions au bénéfice de la BEI, et (ii) l'émission le 18 juillet 2024 des certificats de redevances (les « Certificats de Redevances 2024 ») souscrits par Samsara BioCapital et les actionnaires existants BVF Partners, NEA, Sofinnova et Yiheng, pour un montant de 20,1 millions d'euros. Les Certificats de Redevances 2024 donnent à leurs détenteurs le droit à un paiement annuel de redevances égal à 3 % des ventes nettes futures potentielles de lanifibranor, le cas échéant, aux États-Unis, dans l'Union Européenne et au Royaume-Uni, sur une période de 14 ans à compter de la date de leur émission 6 . Au cours des neufs premiers mois de 2024, la Société n'a pas enregistré d'effet de taux de change sur la trésorerie et les équivalents de trésorerie, contre un effet de taux de change négatif de (- 0,7) million d'euros pour la même période en 2023, en raison de l'évolution du taux de change EUR/USD. Informations financières après clôture des comptes Le 14 octobre 2024, Inventiva a annoncé un financement en plusieurs tranches d'un montant maximum de 348 millions d'euros, provenant d’investisseurs nouveaux et existants 2 . La Société a réalisé la première partie de la première tranche de l’augmentation de capital le 17 octobre 2024 et a émis 34.600.507 nouvelles actions ordinaires (les « Nouvelles Actions T1 ») au prix de 1,35 € par Action Nouvelle T1, ainsi que 35.399.481 bons de souscription ordinaires préfinancés permettant de souscrire à des actions ordinaires de la Société à un prix d'exercice de 0,01 € et un prix de souscription de 1,34 € par nouvelle action ordinaire, et a reçu un produit brut de 94,1 millions d'euros (et environ 86,6 millions d'euros de produit net). La deuxième partie de la première tranche, ainsi que les deuxième et troisième tranches de l’augmentation de capital, sont soumises à la satisfaction de conditions spécifiques, en particulier l’accord des actionnaires. Le 14 octobre 2024, la Société a également annoncé avoir signé un avenant au contrat de licence exclusive et de collaboration avec Chia Tai Tianqing Pharmaceutical (Guangzhou) CO., LTD. («CTTQ »). Dans le cadre de cet amendement, si la Société reçoit des engagements de souscription de la part d’investisseurs de souscrire à une augmentation de capital, en deux ou trois tranches, avant le 31 décembre 2024, pour un montant brut total d’au moins 180 millions d’euros, CTTQ versera à la Société (i) 10 millions de dollars dans les 30 jours suivant le règlement-livraison des nouvelles actions et des bons de souscriptions ordinaires préfinancés, en cas d'émission de la première tranche de l’augmentation de capital, (ii) 10 millions de dollars à l'achèvement de la deuxième tranche de l’augmentation de capital et (iii) 10 millions de dollars à la publication par la Société des données de base positives annonçant que l'un des principaux critères d’évaluation ou l'un des principaux critères d’évaluation secondaires de NATiV3, avec l'un des schémas posologiques testés dans l'essai, ont été atteints. Selon les termes de l'avenant, le montant total des paiements d'étape reste inchangé, tandis que les redevances qu'Inventiva est susceptible de recevoir ont été réduites à un chiffre bas. Le financement annoncé le 14 octobre 2024 a satisfait la condition relative à la réception des engagements pour un montant total d'au moins 180 millions d'euros et la réalisation de la première partie de la première tranche de l'augmentation de capital a satisfait à la condition (i) ci-dessus. Par conséquent, le 18 novembre 2024, la Société a reçu le premier paiement d'étape d'un montant de $10 millions, de la part de CTTQ conformément à cet avenant. Compte tenu de la structure actuelle de ses coûts et des dépenses prévues, et en tenant compte (i) du montant brut de 94,1 millions d’euros provenant de la première partie de la première tranche de l’augmentation de capital, et (ii) le premier paiement d’étape de $10 millions (produits bruts) reçu dans le cadre de l’amendement à l’accord exclusif de licence signé avec CTTQ, la Société estime que sa trésorerie, ses équivalents de trésorerie et ses dépôts lui permettraient de financer ses opérations jusqu'à la fin du deuxième trimestre de 2025. La Société prévoit actuellement que les conditions spécifiques à la réalisation de la deuxième partie de la première tranche de l'augmentation de capital seront remplies en décembre 2024. La Société estime que le montant anticipé des produits (un montant brut de 21,4 millions d'euros) provenant de la deuxième partie de la première tranche de l'augmentation de capital annoncée le 14 octobre 2024 permettra à la Société de financer ses opérations jusqu’au milieu du troisième trimestre de 2025. Chiffres d’affaires Les revenus de la Société pour les neuf premiers mois de 2024 se sont élevés à 1,3 millions d'euros, contre 1,9 million d'euros pour la même période en 2023. *** Prochaines étapes clefs attendues Randomisation du dernier patient de l’étude clinique de Phase 3 NATiV3 évaluant lanifibranor dans la MASH/NASH – attendue au premier semestre 2025 à la suite de la fin du screening attendu pour la fin d’année 2024 Résultats principaux de NATiV3 – attendus pour le deuxième semestre 2026 Prochaine Assemblée Générale Assemblée Générale – 11 décembre 2024 Prochaines participations à des conférences investisseurs 43 rd Annual J.P. Morgan Healthcare conference – 13-16 janvier 2025 – San Francisco 13 th edition of Degroof Petercam’s virtual healthcare conference – 21-24 janvier 2025 Prochaines participations à des conférences scientifiques MASH-TAG – 9-12 janvier 2025 – Park City Prochain rendez-vous financier Chiffre d’affaires et situation de trésorerie pour l’année 2024 : jeudi 13 février 2025 (après clôture des marchés aux Etats-Unis). À propos d’Inventiva Inventiva est une société biopharmaceutique spécialisée dans la recherche et développement de petites molécules administrées par voie orale pour le traitement de patients atteints de la MASH/NASH, et d’autres maladies avec des besoins médicaux non satisfaits significatifs. La Société dispose d’une expérience et d’une expertise significatives dans le développement de composés ciblant les récepteurs nucléaires, les facteurs de transcription et la modulation épigénétique. Inventiva développe actuellement un candidat clinique, dispose d'un portefeuille de deux programmes précliniques et continue d'explorer d'autres opportunités de développement pour étoffer son portefeuille. Lanifibranor, le candidat médicament d’Inventiva le plus avancé, est actuellement évalué dans le cadre de l’étude clinique pivot de Phase 3 NATiV3 pour le traitement de patients adultes atteints de la MASH/NASH, une maladie hépatique chronique courante et progressive. Le portefeuille d'Inventiva comprend également odiparcil, un candidat médicament pour le traitement de patients adultes souffrant de MPS de type VI. Dans le cadre de sa décision de concentrer ses efforts cliniques sur le développement de lanifibranor, Inventiva a suspendu ses efforts cliniques relatifs à odiparcil et examine toutes les options disponibles pour optimiser son développement. Inventiva est également en cours de sélection d’un candidat médicament en oncologie dans le cadre de son programme dédié à la voie de signalisation Hippo. La Société dispose d’une équipe scientifique d'environ 90 personnes dotée d’une forte expertise en biologie, chimie médicinale et computationnelle, pharmacocinétique et pharmacologie ainsi qu’en développement clinique. Inventiva dispose d'une chimiothèque d’environ 240 000 molécules, dont environ 60 % sont exclusives à la Société, ainsi que de ses propres laboratoires et équipements. Inventiva est une société cotée sur le compartiment B du marché réglementé d'Euronext Paris (symbole : IVA - ISIN : FR0013233012) et sur le marché Nasdaq Global Market aux Etats-Unis (symbole : IVA). www.inventivapharma.com . Contacts Avertissement Le présent communiqué de presse contient des "déclarations prospectives" au sens des dispositions de la sphère de sécurité du Private Securities Litigation Reform Act de 1995. Toutes les déclarations, autres que les déclarations de faits historiques, incluses dans ce communiqué de presse sont des déclarations prospectives. Ces déclarations incluent, mais ne se limitent pas à, des informations financières non auditées, des prévisions et des estimations concernant les ressources financières d'Inventiva, les produits anticipés de l'augmentation de capital, l'achèvement et le calendrier de l'augmentation de capital, la satisfaction partielle ou totale des conditions suspensives à la clôture des différentes tranches de l'augmentation de capital et leur calendrier, ainsi que l'exercice par les investisseurs des bons de souscription et des bons de souscription préfinancés émis dans le cadre de l'augmentation de capital, les attentes d'Inventiva concernant son accord de collaboration avec CTTQ, y compris la réalisation des étapes spécifiées dans le cadre de cet accord , les prévisions et les estimations concernant les programmes précliniques et les essais cliniques d'Inventiva, y compris la conception, la durée, le calendrier, les coûts de recrutement, la sélection et le recrutement pour ces essais, ne sont pas limités à ces déclarations, y compris l'essai de Phase 3, NATiV3, avec lanifibranor dans la MASH/NASH, le development clinique et les soumissions réglementaires potentielles, les communiqués et les publications sur les données des essais cliniques, les informations, les idées et les impacts qui peuvent être recueillis à partir des essais cliniques, les avantages thérapeutiques potentiels, les approbations et la commercialisation, le pipeline d'Inventiva et les plans de développement préclinique et clinique, le développement potentiel et la voie réglementaire pour odiparcil, les activités futures, les attentes, les plans, la croissance et les perspectives d'Inventiva et de ses partenaires, et la stratégie commerciale et réglementaire, la commercialisation potentielle de lanifibranor et la réalisation de ventes y afférentes, le paiement potentiel de redevances et la performance future anticipée. Certaines de ces déclarations, prévisions et estimations peuvent être reconnues par l’utilisation de mots tels que, sans limitation, « croit », « anticipe », « s’attend à », « projette », « planifie », « cherche », « estime », « peut », « sera », « pourrait », « devrait », « conçu », « espère », « cible », « vise » et « continue » et autres expressions similaires. Ces déclarations ne sont pas des faits historiques mais plutôt des déclarations d'attentes futures et d'autres déclarations prospectives fondées sur les convictions de la direction. Ces déclarations reflètent les opinions et les hypothèses qui prévalent à la date des déclarations et impliquent des risques connus et inconnus ainsi que des incertitudes qui pourraient entraîner une différence matérielle entre les résultats futurs, les performances ou les événements futurs et ceux qui sont exprimés ou sous-entendus dans ces déclarations. Les événements réels sont difficiles à prévoir et peuvent dépendre de facteurs qui échappent au contrôle d'Inventiva. Il n'y a aucune garantie, en ce qui concerne les produits candidats, que les résultats des essais cliniques seront disponibles dans les délais prévus, que les essais cliniques futurs seront lancés comme prévu, que les produits candidats recevront les autorisations réglementaires nécessaires, ou que les étapes prévues par Inventiva ou ses partenaires seront atteintes dans les délais prévus, ou même qu'elles le seront. Les résultats réels peuvent s'avérer matériellement différents des résultats, performances ou réalisations futurs anticipés exprimés ou sous-entendus par ces déclarations, prévisions et estimations en raison d'un certain nombre de facteurs, y compris l'achèvement des procédures de clôture financière, les ajustements finaux des résultats financiers pour le premier semestre 2024 qui seront communiqués ultérieurement dans le rapport financier semestriel, le résultat de l'examen des états financiers de la société par les commissaires aux comptes, y compris l'utilisation de la méthode de la continuité de l'exploitation et les informations divulguées dans les états financiers de la société, y compris le fait qu'Inventiva ne peut pas fournir d'assurance sur les impacts du SUSAR sur le recrutement ou l'impact final sur les résultats ou le calendrier de l'essai NATiV3 ou les questions réglementaires qui s'y rapportent, Inventiva est une société en phase clinique qui n'a pas de produits approuvés et n'a pas de revenus historiques, Inventiva a subi des pertes importantes depuis sa création, Inventiva a un historique d'exploitation limité et n'a jamais généré de revenus à partir de la vente de produits, Inventiva aura besoin de capitaux supplémentaires pour financer ses activités, faute de quoi elle pourrait être obligée de réduire, de retarder ou d'interrompre de manière significative un ou plusieurs de ses programmes de recherche ou de développement, ou être incapable d'étendre ses activités ou de tirer parti de ses opportunités commerciales, et pourrait ne pas être en mesure de poursuivre ses activités, la capacité d'Inventiva à obtenir des financements et à conclure des transactions potentielles, les transactions et la capacité d'Inventiva à satisfaire partiellement ou complètement aux conditions suspensives pour les tranches supplémentaires de l'augmentation de capital et aux conditions liées à CTTQ, ainsi que la question de savoir si et dans quelle mesure les bons de souscription peuvent être exercés et par quels détenteurs, le succès futur d'Inventiva dépend de la réussite du développement clinique, des approbations réglementaires et de la commercialisation ultérieure des produits candidats actuels et futurs, les études précliniques ou les essais cliniques antérieurs ne sont pas nécessairement prédictifs des résultats futurs et les résultats des essais cliniques d'Inventiva et de ses partenaires peuvent ne pas étayer les revendications d'Inventiva et de ses partenaires concernant les produits candidats, les attentes d'Inventiva concernant ses essais cliniques peuvent s'avérer erronées et les autorités réglementaires peuvent exiger des arrêts et/ou des modifications des essais cliniques d'Inventiva, les attentes d'Inventiva concernant les changements du plan de développement clinique du lanifibranor pour le traitement de la MASH/NASH peuvent ne pas se réaliser et ne pas soutenir l'approbation d'une demande de nouveau médicament (New Drug Application), Inventiva et ses partenaires peuvent rencontrer des retards substantiels au-delà des attentes dans leurs essais cliniques ou échouer à démontrer la sécurité et l'efficacité à la satisfaction des autorités réglementaires applicables, la capacité d'Inventiva et de ses partenaires à recruter et à retenir des patients dans les études cliniques, le recrutement et la rétention de patients dans les études cliniques est un processus coûteux et chronophage qui pourrait être rendu plus difficile ou impossible par de multiples facteurs échappant au contrôle d'Inventiva et de ses partenaires, les produits candidats d'Inventiva peuvent provoquer des réactions indésirables ou avoir d'autres propriétés qui pourraient retarder ou empêcher leur approbation réglementaire, ou limiter leur potentiel commercial, Inventiva doit faire face à une concurrence importante, et les activités d'Inventiva et de ses partenaires, les études précliniques et les programmes de développement clinique ainsi que les calendriers, la situation financière et les résultats d'exploitation d'Inventiva pourraient être affectés de manière significative et négative par des événements géopolitiques, tels que le conflit entre la Russie et l'Ukraine et les sanctions qui en découlent, les impacts et les impacts potentiels sur le lancement, le recrutement et l'achèvement des essais cliniques d'Inventiva et de ses partenaires dans les délais prévus, l'état de guerre entre Israël et le Hamas et le risque connexe d'un conflit plus important, les épidémies, et les conditions macroéconomiques, y compris l'inflation mondiale, la hausse des taux d'intérêt, les marchés financiers incertains et les perturbations dans les systèmes bancaires. L'examen des options financières et stratégiques potentielles peut ne pas aboutir à une transaction particulière, et il n'y a aucune garantie quant au calendrier, à la séquence ou à l'issue d'une transaction ou d'une série de transactions. Si Inventiva n'est pas en mesure de poursuivre ses activités, elle pourrait devoir liquider ses actifs et recevoir moins que la valeur à laquelle ces actifs sont comptabilisés dans ses états financiers, et il est probable que les investisseurs perdront tout ou partie de leur investissement. Compte tenu de ces risques et incertitudes, aucune déclaration n'est faite quant à l'exactitude ou à la sincérité de ces déclarations prospectives, prévisions et estimations. En outre, les déclarations prospectives, les prévisions et les estimations ne sont valables qu'à la date du présent communiqué de presse. Les lecteurs sont invités à ne pas accorder une confiance excessive à ces déclarations prévisionnelles. Veuillez vous référer au Document de Référence Universel pour l'exercice clos le 31 décembre 2023, déposé auprès de l'Autorité des Marchés Financiers le 3 avril 2024, tel que modifié le 14 octobre 2024, et au Rapport Annuel sur le Formulaire 20-F pour l'exercice clos le 31 décembre 2023, déposé auprès de la Securities and Exchange Commission le 3 avril 2024, et au Rapport Semestriel pour les six mois clos le 30 juin 2024 déposé auprès de la SEC le 15 octobre 2024. D'autres risques et incertitudes dont Inventiva n'a pas actuellement connaissance peuvent également affecter ses déclarations prospectives et faire en sorte que les résultats réels et le calendrier des événements diffèrent sensiblement de ceux anticipés. Toutes les informations contenues dans ce communiqué de presse sont à jour à la date du communiqué. Sauf obligation légale, Inventiva n'a ni l'intention ni l'obligation de mettre à jour ou de réviser les déclarations prospectives mentionnées ci-dessus. Par conséquent, Inventiva n'accepte aucune responsabilité pour les conséquences découlant de l'utilisation de l'une des déclarations susmentionnées. 1 Information financière non auditée. 2 Communiqué de presse du 14 octobre 2024 3 Cette estimation est basée sur le plan d'affaires actuel de la Société et exclut tout paiement d’étape potentiel à ou par la Société et toute dépense supplémentaire liée à la poursuite potentielle du développement du programme odiparcil ou résultant de l'octroi potentiel de licences ou de l'acquisition de produits candidats ou de technologies supplémentaires, ou de tout développement associé que la Société pourrait poursuivre. La Société a peut-être basé cette estimation sur des hypothèses incorrectes, et pourrait finir par utiliser ses ressources plus rapidement que prévu. 4 Les dépôts à court terme étaient classés dans la catégorie « autres actifs courants » dans l’état consolidé de la situation financière selon les normes IFRS, et étaient considérés par la Société comme liquides et facilement disponibles. 5 Le dépôt à long terme d’une durée de deux ans était accessible avant expiration du terme avec un préavis de 31 jours et était considéré comme liquide par la Société. 6 Communiqué de presse du 18 juillet 2024 Pièce jointe Inventiva - CP - Q3 2024 CA Cash - FR - 11 21 2024 - Final

Revolutionizing Trash Collection for Texas: Food Cycle Science and Waste Connections Team Up with Canton, Texas to Combat Food Waste

It took far longer than anyone in the organization preferred, but the Utica Comets finally ended its winless streak. The Comets notched a 4-3 win Friday at the Syracuse Crunch — eventual American Hockey League Player of the Week Mike Hardman scored the game-winner with 73 seconds remaining — and then showed an opportunistic side less than 24 hours later in a 5-1 road victory over the Rochester Americans. Both Isaac Poulter (26 saves Friday) and Nico Daws (35 saves Saturday) were sharp in earning their first wins of the season. The results snapped the team-record 13-winless streak to start the season (technically 14, dating to the 23-24 season finale). The wins give the Comets a 2-10-2-1 overall record, getting them a step closer to no longer having the worst record in the 32-team league. Saturday's five goals were a season-best. Notably, the team totaled nine goals over the two wins which constitutes 30% of the total goals this season. The offensive outburst is a positive step for the Comets, who were averaging 1.6 goals per game entering the weekend. Hardman earns honor For his play on the weekend, Hardman was named Player of the Week on Monday. It is the first time the 25-year-old winger has earned the AHL's weekly award. Hardman totaled four points, including the eventual game-winners on Friday and Saturday. Hardman, returning from a three-game injury absence, had an assist to help give Utica a two-goal lead on Friday, before scoring two go-ahead goals in the third period, the second one coming with 1:13 remaining to help Utica get the win. Hardman, a fourth-year pro from Massachusetts, has four goals and one assist in seven games with the Comets this season. He signed as a free agent with the parent New Jersey Devils in the offseason. He's is the first Comets player to be named AHL Player of the Week since Dec. 25, 2022 (Graeme Clarke). Hardman is the eighth Comets player to earn the weekly honor since 2013. Holding off Syracuse Comets' captain Ryan Schmelzer ended two other droughts with the game's opening goal in the first period Friday in Syracuse. It was his first goal of the season and it snapped a stretch of 138 minutes the team had gone without a goal over parts or all of four games. While on the power play, Schmelzer circled into the left faceoff dot and took a snap pass from rookie defenseman Seamus Casey and one-timed a rocket past sprawling goaltender Matt Tomkins. The Comets had not scored in a 2-0 loss at home the previous weekend. Utica;s lead doubled when Beckman got his second point of the night, 2:41 into the second period. When the puck came out from along the boards in the offensive zone, Hardman took a shot from far out as Beckman drove the net and tipped it in over Tomkins' glove. It was Beckman's third goal of the season and Hardman's first assist. Syracuse cashed on two power plays in the second and third period to tie the game. Hardman grabbed the lead back with his second goal of the season with just under 10 minutes left in regulation. The puck was pushed to him on a rebound, and he ripped a shot from the right faceoff circle that hit the back of the net, putting the Comets up 3-2. The Crunch's Conor Sheary then tied the game with 4:40 left in regulation. However, a second power-play tally for the Comets was the goal that finally ended the winless streak. Hardman sent a rebound off his own initial shot past Tomkins. After work on special teams leading into the game, Utica finished 2-for-3 on the power play. Though, the penalty kill finished 1-for-3. It was the first AHL coaching win for interim coach Ryan Parent. Rolling past Rochester While it wasn't the prettiest of outings — Utica had six total shots through 26 minutes of game time, for example — Utica was opportunistic Saturday in Rochester. It snapped a three-game winless streak vs. the Amerks. It helped Utica's power play also scored twice, including the first goal of the game 8:44 into the opening period by Brian Halonen. He scored through a mess of bodies in front after a short pass from Xavier Parent. Utica's three-goal second period helped give the team a 4-0 lead and Comets came within 10.8 seconds of shutting out the Amerks before Brendan Warren scored the Amerks' only goal in the 5-1 loss. Utica extended the lead to 4-0 over a less than nine-minute span with goals from Hardman (from the bottom of the right circle), Halonen (one-timer from the left circle on the power play) and Nathan Légaré tapping in the puck on feed from Topias Vilen on the rush. That goal ended Felix Sandstrom’s night (11 saves on 15 shots). Schmelzer scored from the top of the right circle near the midpoint of the third. It was the sixth loss in seven games for Rochester. Casey, points leader Casey, playing in his 11th game with Utica, finished with back-to-back two-point games. He leads the team 13 points, including a team-best 12 assists. His points are tied for seventh among all AHL rookies. Upcoming The Comets have their final home game of November at 7 p.m. Wednesday against Providence. It is the first of two visits for Boston's AHL affiliate. Utica then heads to Springfield for a 4:05 p.m. game Friday in Massachusetts. Then, Utica meets Providence again at 7 p.m. Saturday in Rhode Island to close November.

Centennial beats Northern champ, wins 2nd straight football state title

How digitalisation is transforming trade in Africa

As they traverse their financial paths, affluent people actively seek out the best private wealth management possibilities and tools because they have high aspirations for both them and their wealth. However, their wealth managers typically provide this group with the typical financial advisory expertise. Approximately 46% of wealthy respondents stated that wealth management companies do not provide them with value-added services, and nearly one-third thought that robo-advisory services did not adequately address their inquiries. They genuinely want individualized assistance in making investment choices, to be involved and informed about value-added solutions, and to have someone who can respond to inquiries that a pure-tech model cannot. With DBS Treasures Private Client, DBS Bank has accelerated the wealth path of prosperous professionals and entrepreneurs around the region by utilizing this physical method to uncover opportunities and technologies that were previously exclusive to ultra-high net worth clients. Additionally, customers can effortlessly switch to the bank’s upscale private wealth management services when the time comes. About 2,000 clients have migrated up the wealth continuum over the last two to three years, from the DBS Treasures Singapore platform, which has an investible asset minimum of S$350,000 (US$257,011), to the Treasures Private Client platform, which has an investible asset minimum of S$1.5 million (US$1.1 million). Accelerate Your Path to Wealth DBS Treasures uses machine learning (ML) and artificial intelligence (AI) technologies to deliver timely, personalized advice and services that align with their clients’ personal and financial objectives. From hedge fund investments and structured securities to international property finance options and estate planning, these include a range of alternatives intended to assist them in producing returns in accordance with their risk tolerance. In order to create robust portfolios with a mix of stability and growth, clients can also take advantage of the bank’s in-house wealth management solutions, which are founded on a “Core-Satellite” methodology. Along with other assets to spread and efficiently manage risk, the core component is made up of a diverse mix of asset classes, such as bonds for steady cash flow and stocks for possible high returns. The satellite component, meanwhile, provides the adaptability to seize transient market opportunities and raise total investment returns. Under the Core-Satellite concept, the bank uses a variety of investing methods aimed at improving the resilience of a portfolio. By making significant investments in assets at both extremes of the risk spectrum, the Barbell strategy, for example, aims to strike a balance between risk and profit. Another approach called I.D.E.A., which is divided into Innovators, Disruptors, Enablers, and Adapters, seeks to pinpoint industries and businesses that are most likely to succeed in the digital economy. Additionally, the Wealth Management Account allows clients to easily examine and manage their portfolios, trade stocks, buy funds (including those that are only accessible to accredited investors), and conduct foreign currency operations. They also have prompt access to expert views and well-chosen investment ideas. Always put safety first. The wealthy investors of today don’t mind taking chances, but in a world that is unpredictable and always changing, protecting one’s fortune is just as crucial as increasing it. DBS Treasures is supported by the globally recognized strength of the DBS Group, which has been rated Aa1 by Moody’s and AA- by S&P Global Ratings. Among other honours, DBS has been named Asia’s Best Bank for Wealth Management by Euromoney and the World’s Best Bank and Safest Bank in Asia by Global Finance for 15 consecutive years. Having Access to a Worldwide Network In a more unstable global environment, diversity has gained more attention as a strategy for generating profits and reducing risk. In order to better diversify their portfolios, wealthy investors are increasingly looking for access to markets outside of their native countries. Many DBS Treasures clients will eventually reach a point where they are prepared to start a new chapter with DBS Treasures Private Client and the capabilities provided on that higher platform as their wealth increases. This change can be made by clients without affecting their experience.(The Center Square) – House Oversight Chair Rep. James Comer, R-Ky., has opened an investigation into the Federal Emergency Management Agency over reports that it discriminated against supporters of Donald Trump. Comer said whistleblower reports suggest anti-Trump discrimination is rampant and has been going on for years. “[O]n the condition of anonymity, a FEMA official stated that the practice avoiding ‘white or conservative-dominated’ areas is an ‘open secret at the agency that has been going on for years,’” Comer said in a letter to FEMA. The investigation comes after FEMA fired one of its hurricane response supervisors after news went viral that she told her workers to avoid “Trump houses.” However, that employee has publicly said she was only following orders and acting according to the culture at FEMA. Comer and more than two dozen Republican lawmakers sent a letter to FEMA Administrator Deanne Criswell demanding documentation, from internal policies to spending figures to incident reports. Lawmakers have pointed toward more anonymous sources backing up the fired employee’s claims. “Additionally, another whistleblower contacted the Committee during the hearing," the letter said. "This individual informed the Committee that a FEMA contractor warned a disabled veteran’s family in Georgia to remove Trump campaign materials from their home because FEMA supervisors viewed Trump supporters as domestic terrorists. At a hearing this week, U.S. Rep. Greg Steube, R-Fla., pointed to 35 of his constituents who shared similar stories with him. Lawmakers grilled Criswell over the discrimination reports at the hearing as well as FEMA’s recent focus on Diversity Equity and Inclusion efforts, something FEMA named as its number one goal in its latest strategic report. Lawmakers also raised concerns about the agency spending hundreds of millions of dollars on helping migrants. Defenders of FEMA have said the migrant funds do not take directly from disaster relief, while critics insist it shows missplaced priorities for the emergency relief agency. “In the fiscal year of 2023, FEMA spent nearly a billion dollars, $789 million, to shelter illegals in the United States,” Rep. Marjorie Taylor Green, R-Ga., said at the hearing, as The Center Square previously reported . “This past year it was $641 million, and this money is largely distributed through NGOs...and this was to house illegal aliens," she added. "Not Americans, who by the way all that money, that comes from Americans bank accounts when they write their checks to pay their taxes." At the hearing this week, Criswell also said she will request the Inspector General investigate the question of political discrimination at FEMA. She also said she does not think this fired employee is indicative of a broader problem in the agency but is looking into it. Criswell said FEMA workers went back to the homes that were skipped over by the fired employee and promised to ensure it doesn't happen again. “The Committee is in the process of investigating these claims,” the Oversight letter said. “If they are true, they would corroborate concerns that political discrimination extends beyond [the fired FEMA employee]. Furthermore, they suggest an apparent culture, whether sanctioned or not, within FEMA to politically discriminate against disaster survivors, specifically those who support President-elect Donald Trump.”

US special prosecutor drops criminal cases against President-elect TrumpNEW YORK (AP) — Sean “Diddy” Combs was denied bail on Wednesday as he awaits a May sex trafficking trial by a judge who cited evidence showing him to be a “serious risk” of witness tampering and proof he has tried to hide prohibited communications with third parties while incarcerated. U.S. District Judge Arun Subramanian ruled in a five-page order following a bail hearing last week. At the hearing, lawyers for the hip-hop mogul argued that a $50 million bail package they proposed would be sufficient to ensure Combs doesn’t flee and doesn’t try to intimidate prospective trial witnesses. Two other judges previously had agreed with prosecutors that the Bad Boy Records founder was a danger to the community if he is not behind bars. Subramanian concurred. “There is compelling evidence of Combs's propensity for violence,” Subramanian wrote. Lawyers for Combs did not immediately respond to messages seeking comment on the decision. Nicholas Biase, a spokesperson for prosecutors, declined comment. Combs, 55, has pleaded not guilty to charges that he coerced and abused women for years, aided by associates and employees. An indictment alleges that he silenced victims through blackmail and violence, including kidnapping, arson and physical beatings. A federal appeals court judge last month denied Combs’ immediate release while a three-judge panel of the 2nd U.S. Circuit Court of Appeals in Manhattan considers his bail request. That appeal was put on hold while Subramanian, newly appointed to the case after an earlier judge stepped aside, considered the bail request for the first time. Subramanian said he took a fresh look at all the bail arguments and the evidence supporting them to make his decision. Prosecutors have insisted that no bail conditions would be sufficient to protect the public and prevent the “I'll Be Missing You” singer from fleeing. They say that even in a federal lockup in Brooklyn, Combs has orchestrated social media campaigns designed to influence prospective jurors and tried to publicly leak materials he thinks can help his case. They say he also has contacted potential witnesses through third parties. Lawyers for Combs say any alleged sexual abuse described in the indictment occurred during consensual relations between adults and that new evidence refutes allegations that Combs used his “power and prestige” to induce female victims into drugged-up, elaborately produced sexual performances with male sex workers known as “Freak Offs.” Subramanian said evidence shows Combs to be a “serious risk of witness tampering,” particularly after he communicated over the summer with a grand jury witness and deleted some of his texts with the witness. The judge also cited evidence showing that Combs violated Bureau of Prisons regulations during pretrial detention at the Metropolitan Detention Center in Brooklyn when he paid other inmates to use their phone code numbers so he could make calls to individuals who were not on his approved contact list. He said there was also evidence that he told family members and defense counsel to add other people to three-way calls so their communications would be more difficult to trace and that he made efforts to influence his trial's jury pool or to reach potential witnesses. Subramanian said his “willingness to skirt” jailhouse rules to conceal communications was “strong evidence” that any conditions of release would not prevent similar behavior. The judge said defense claims that Combs stopped using one particular phone technique criticized by prosecutors was belied by the fact that Combs apparently used it again on Sunday, two days after his bail hearing last week. Even a bail proposal that would include the strictest form of home confinement seemed insufficient, the judge said. “Given the nature of the allegations in this case and the information provided by the government, the Court doubts the sufficiency of any conditions that place trust in Combs and individuals in his employ — like a private security detail — to follow those conditions,” Subramanian wrote.